|AHFS/Drugs.com||International Drug Names|
|ATCvet code||QA08AB91 (WHO)|
|Biological half-life||5–18 hours (increased with repeated dosing)|
|Chemical and physical data|
|Molar mass||674.71 g/mol|
|3D model (Jmol)||Interactive image|
It works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.
It is supplied as an oral solution. It is not intended for use in humans, cats, birds, rodents, or other animals.
Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It is used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma.
Regulation and safety
On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs.
However, concerns have since been raised, since 2010, about adverse effects that might more strongly affect particular breeds.
- "Slentrol (dirlotapide) Oral Solution (5 mg/ml, 1%) for Use in Dogs Only. Full Prescribing Information" (PDF). zoetisUS.com. Pfizer Animal Health. Div. of Pfizer Inc. NY, NY 10017. Retrieved 28 November 2015.
- Klonoff, DC (2007). "Dirlotapide, a U.S. Food and Drug Administration-approved first-in-class obesity drug for dogs-will humans be next?". J Diabetes Sci Technol. 1: 314–6. doi:10.1177/193229680700100301. PMC 2769592. PMID 19885086.
- Bridges, Andrew. "FDA approves 1st drug for obese dogs". Associated Press. Archived from the original on January 8, 2007. Retrieved January 6, 2007 – via Yahoo! News.